VRCA logo

VRCAVerrica Pharmaceuticals Inc

$6.03
$0.275
(4.78%)
Today
Closed $6.03
$0.325
(5.39%)
After Hours
Updated: 04:33 PM EDT
EarningsAug 12
Mkt Cap$98.78M
Vol38,224.00
News
all
press releases
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
read more...
Benzinga
News Placeholder
More News
News Placeholder
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Lipocine (LPCN) delivered earnings and revenue surprises of -5.88% and +19.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +15.31% and +9.80%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday
Verrica Pharmaceuticals (NASDAQ:VRCA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
News Placeholder
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 581,329 shares, a growth of 16.8% from the March 31st total of 497,753 shares. Based on an average...
MarketBeat
News Placeholder
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Reduce" by Brokerages
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has earned an average rating of "Reduce" from the four ratings firms that are currently covering the company, MarketBeat.com reports. Two...
MarketBeat
News Placeholder
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Growth in Short Interest
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 478,579 shares, a growth...
MarketBeat
News Placeholder
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts
Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation an...
MarketBeat
News Placeholder
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ...
Business Wire
<
1
2
...
>

Advertisement|Remove ads.